Fact-checked by Grok 2 weeks ago

Common cold

The common cold, also known as a common upper respiratory infection (URI), is a mild, self-limiting viral illness primarily affecting the mucous membranes of the nose and throat.^[1] It is caused by more than 200 different respiratory viruses, with rhinoviruses accounting for the majority of cases, alongside others such as coronaviruses, parainfluenza viruses, adenoviruses, enteroviruses, and human metapneumovirus.^[1] Symptoms typically develop 1–3 days after exposure and include a runny or stuffy nose, sneezing, sore or scratchy throat, cough, mild body aches, headache, and sometimes a low-grade fever, though these are generally less severe than those of influenza.^[2] The illness is highly contagious, spreading through respiratory droplets from coughing or sneezing, direct contact with contaminated surfaces, or close personal interaction, and it occurs year-round but peaks during colder months in temperate climates.^[1] In the United States, adults experience an average of 2–3 colds per year, while young children may have 6–8 or more due to their developing immune systems and frequent exposure in group settings like schools.^[2] Most cases resolve without complications within 7–10 days, though symptoms like cough or congestion can linger up to two weeks, and smokers or those with weakened immunity may experience prolonged or more intense effects.^[3] There is no specific cure or vaccine for the common cold, as its viral nature renders antibiotics ineffective except in cases of secondary bacterial infections; treatment focuses on symptom relief through rest, hydration, over-the-counter remedies like decongestants, pain relievers, and saline nasal sprays.^[1] Prevention relies on basic hygiene measures, including frequent handwashing with soap for at least 20 seconds, covering the mouth and nose when coughing or sneezing, avoiding close contact with infected individuals, and disinfecting frequently touched surfaces.^[2] Although usually harmless, the common cold can lead to complications such as sinusitis, middle ear infections, or exacerbations of underlying conditions like asthma, particularly in vulnerable populations including infants, the elderly, and those with chronic illnesses.^[3]

Signs and symptoms

Common symptoms

The common cold is characterized by a range of upper respiratory symptoms, primarily affecting the nose, throat, and sinuses, resulting from viral infection and subsequent immune responses.^[1] The hallmark symptoms include rhinorrhea (runny nose) and nasal congestion, which arise from inflammation of the nasal mucosa triggered by viral replication and the release of inflammatory mediators such as bradykinin and prostaglandins, leading to increased vascular permeability and mucus production by goblet cells.^[4] Sneezing accompanies these nasal issues as a reflex response to irritation of the nasal epithelium, expelling irritants and aiding viral spread.^[5] Sore throat, or pharyngitis, is another frequent early symptom, caused by local inflammation and sensory nerve stimulation in the pharynx due to viral invasion and cytokine release.^[4] Cough often follows, initially presenting as a dry, non-productive type from heightened airway sensitivity and irritation, but potentially becoming productive with mucus clearance as inflammation progresses.^[1] Accompanying systemic symptoms such as headache and mild fatigue stem from pro-inflammatory cytokines like interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-α), which induce sickness behavior, including malaise and pain sensitization in the central nervous system.^[5] Less common manifestations include low-grade fever, muscle aches, and watery eyes. Fever, typically mild (below 100.4°F or 38°C), results from cytokines acting on the hypothalamus to elevate the body's temperature set point, and it occurs more frequently in young children than in adults due to differences in immune maturation.^[6] Muscle aches arise from prostaglandin-mediated inflammation and cytokine effects on muscle tissue, while watery eyes occur secondary to nasolacrimal duct inflammation and increased tear production.^[4] Symptom severity generally remains mild across age groups, though children under 6 years old experience more intense nasal symptoms and higher fever incidence compared to adults.^[5]

Progression and duration

The common cold typically follows a predictable progression following viral exposure. The incubation period lasts 1 to 3 days, during which the virus replicates in the upper respiratory tract without noticeable symptoms.^[2] In the acute phase, spanning days 1 to 3 after symptom onset, initial signs emerge including sneezing, nasal irritation, sore throat, headache, chilliness, and malaise, as the immune response begins to manifest.^[7] These early symptoms reflect the virus's initial impact on the nasal mucosa and adjacent tissues. Symptom severity often reaches its height within the first 2 to 3 days after onset, with worsening nasal congestion, increased cough, and fatigue becoming prominent as inflammation intensifies.^[1]^[7] During the resolution phase, from days 7 to 10, symptoms gradually subside, with most individuals experiencing improvement in nasal and throat issues, though cough may linger for up to 2 to 3 weeks in some cases.^[7] The average total duration is 7 to 10 days in adults, while it can extend to 10 to 14 days in children due to their developing immune systems.^[8] Factors such as overall immune status can influence the length and severity of the illness, with immunocompromised individuals potentially facing prolonged recovery.^[7]

Causes

Viral etiology

The common cold is primarily caused by a variety of viruses from several families, with viral infections accounting for nearly all cases.^[9] Among these, rhinoviruses are the predominant etiologic agents, responsible for 50-80% of common cold episodes depending on the season and population studied.^[10] Rhinoviruses belong to the Picornaviridae family and exist in over 100 serotypes, which contributes to their ability to repeatedly infect individuals by evading prior immunity.^[10] Other viruses implicated in the common cold include coronaviruses, which cause approximately 10-20% of cases and are more prevalent during winter months.^[11] Respiratory syncytial virus (RSV) is another key contributor, particularly in children under five years old, where it accounts for a significant proportion of upper respiratory infections resembling the common cold.^[12] Additional causative agents encompass parainfluenza viruses, adenoviruses, enteroviruses, and human metapneumovirus, each responsible for smaller but notable fractions of cases, often varying by geographic region and age group.^[10] The structural differences between non-enveloped and enveloped viruses influence their environmental stability and potential for infectivity in the context of the common cold. Non-enveloped viruses like rhinoviruses and adenoviruses lack a lipid envelope, rendering them more resistant to desiccation, heat, and common disinfectants, which allows them to persist longer on surfaces and in aerosols.^[13] In contrast, enveloped viruses such as coronaviruses and parainfluenza viruses are more fragile outside the host due to their sensitive lipid bilayer, reducing their survival time in the environment but not necessarily their transmissibility through direct contact or droplets.^[13] Bacterial causes of the common cold are exceedingly rare, with studies confirming that primary bacterial infections represent less than 1% of cases, underscoring the overwhelmingly viral nature of the illness.^[9] Since 2020, certain variants of SARS-CoV-2 have emerged as occasional causes of mild upper respiratory infections that clinically resemble the common cold, particularly in vaccinated or previously exposed populations; as of 2025, these account for a variable but minor proportion of such cases amid ongoing seasonal surges.^[14]^[15]

Transmission

The common cold is primarily transmitted through respiratory droplets and aerosols generated by infected individuals during coughing, sneezing, or talking. Large-particle droplets greater than 10 µm in diameter are expelled and can infect susceptible persons upon direct contact with the nasal or conjunctival mucosa, typically within close proximity (about 1-2 meters). Smaller aerosols under 5 µm can remain suspended longer and infect via inhalation into the respiratory tract, though rhinoviruses—the most common cause—are thought to spread mainly via larger droplets with some contribution from short-range aerosols.^[8] Indirect transmission occurs via contaminated environmental surfaces, or fomites, such as doorknobs, toys, or shared objects, where viruses like rhinoviruses can survive for extended periods. Rhinoviruses remain infectious on hands for up to 2 hours and on non-porous inanimate surfaces for several days, up to 4 days under ideal conditions, facilitating transfer to fingertips during routine contact. A key secondary route involves self-inoculation, where contaminated hands touch the nasal mucosa, eyes, or mouth, leading to infection; experimental studies confirm this mechanism in both hand-to-hand and hand-to-surface scenarios.^[8]^[11]^[16] Infectivity is highest during the symptomatic phase, with viral shedding peaking on days 2-7 after symptom onset, though shedding can begin a few days prior to symptoms and persist for up to 3-4 weeks in some cases. Asymptomatic shedding contributes to transmission, particularly in the early incubation period (12-72 hours before symptoms), allowing spread from pre-symptomatic or mildly affected individuals. Transmission is amplified in settings of close contact, such as households and schools, where secondary attack rates for human rhinovirus infections range from 25% to 70%, driven by frequent interactions among family members or children.^[11]^[17]

Predisposing factors

Several factors can weaken the immune system and thereby increase susceptibility to common cold infections. Chronic stress elevates cortisol levels, which suppress immune cell activity and reduce the body's ability to fight viral invaders.^[18] Sleep deprivation similarly impairs immune function by decreasing the production of protective cytokines and antibodies, making individuals more prone to upper respiratory infections.^[18] Malnutrition, particularly deficiencies in vitamins A, C, D, and zinc, compromises both innate and adaptive immunity, leading to higher rates of respiratory infections including the common cold.^[19] Environmental exposures play a significant role in elevating common cold risk by facilitating viral transmission and impairing host defenses. Crowded living conditions increase close-contact opportunities for virus spread, as seen in studies of college dormitories where high occupancy correlates with elevated respiratory infection rates.^[20] Poor ventilation in enclosed spaces allows airborne viruses to accumulate, heightening exposure risks for rhinoviruses and other cold-causing pathogens.^[21] Low indoor humidity dries out nasal mucosa, reducing mucociliary clearance and creating a more favorable environment for viral replication and infection.^[22] Age-related vulnerabilities are particularly pronounced in young children, who experience higher incidence of common colds due to their immature immune systems, which respond less effectively to novel viral antigens.^[23] School and daycare settings exacerbate this risk through frequent exposure to infected peers, resulting in children averaging 6-10 colds per year compared to 2-4 in adults.^[24] Certain chronic conditions further predispose individuals to common cold infections by compromising mucosal barriers in the respiratory tract. Asthma patients exhibit heightened vulnerability to rhinovirus infections, the primary cause of colds, due to impaired epithelial integrity and dysregulated antiviral responses.^[25] Smoking damages the respiratory epithelium, impairs ciliary function, and alters local immunity, significantly increasing the risk of acquiring and experiencing prolonged common cold symptoms.^[26] Seasonal variations in immune function contribute to fluctuating susceptibility to common colds, with shorter day lengths in winter associated with reduced antiviral defenses and higher infection rates.^[27] This modulation involves rhythmic changes in immune cell activity and cytokine production, independent of direct viral exposure patterns.^[28]

Pathophysiology

Viral mechanisms

The common cold is primarily caused by viruses from the Picornaviridae family, such as rhinoviruses, and Coronaviridae family, including human coronaviruses like 229E, NL63, OC43, and HKU1, each employing distinct mechanisms to invade and replicate within respiratory epithelial cells.^[29]^[30] Rhinoviruses, non-enveloped single-stranded RNA viruses, initiate infection through attachment to specific receptors on the surface of respiratory epithelial cells. The major group of rhinoviruses, comprising over 90% of serotypes, binds to intercellular adhesion molecule-1 (ICAM-1) via a conserved canyon structure on the viral capsid, facilitating close contact with the host cell membrane.^[29] In contrast, the minor group utilizes low-density lipoprotein receptors (LDLR) or related proteins, binding near the five-fold vertex of the capsid.^[29] Following attachment, entry occurs via receptor-mediated endocytosis, where the virus is engulfed into an endocytic vesicle.^[29] Uncoating of rhinoviruses involves the release of the positive-sense RNA genome into the host cytoplasm. For the major group, ICAM-1 binding triggers conformational changes in the capsid, leading to immediate RNA ejection even at neutral pH; minor group viruses, however, require endosomal acidification (pH ~5.5) to destabilize the capsid and liberate the RNA.^[29] Once in the cytoplasm, the RNA serves as a template for translation into a polyprotein, which viral proteases (2Apro and 3Cpro) cleave into functional components, including the RNA-dependent RNA polymerase (3Dpol).^[29] Replication proceeds rapidly in cytoplasmic replication complexes, producing new genomic RNA strands via negative-strand intermediates, with a full cycle completing in approximately 6-8 hours and yielding hundreds of progeny virions per infected cell.^[29] New rhinovirus particles assemble in the cytoplasm and are released upon host cell lysis, which disrupts the epithelial barrier and propagates local infection through direct spread to adjacent cells.^[29] This lytic release contributes to tissue damage and the inflammatory response characteristic of the common cold.^[29] In comparison, human coronaviruses causing the common cold are enveloped positive-sense RNA viruses with more complex entry and release mechanisms. Attachment is mediated by the spike (S) glycoprotein binding to host receptors: human aminopeptidase N (APN) for HCoV-229E, angiotensin-converting enzyme 2 (ACE2) for HCoV-NL63, and sialic acids (e.g., N-acetyl-9-O-acetylneuraminic acid) for HCoV-OC43 and HKU1.^[30] Entry follows receptor binding via endocytosis, with subsequent fusion of the viral envelope and endosomal membrane, often requiring proteolytic cleavage of the S protein by host enzymes like cathepsins or TMPRSS11D to expose the fusion peptide.^[30] Uncoating releases the coronavirus RNA genome into the cytoplasm after membrane fusion, without the need for capsid destabilization seen in non-enveloped viruses.^[30] Replication occurs in double-membrane vesicles derived from host membranes, where the genomic RNA is translated into replicase polyproteins (pp1a and pp1ab) that form a complex to synthesize full-length negative-sense RNA intermediates and subsequently new genomic and subgenomic RNAs via discontinuous transcription.^[30] The cycle, while not precisely timed in literature for these mild strains, mirrors the efficient replication of related coronaviruses, leading to high viral yields.^[30] Unlike the lytic release of rhinoviruses, coronaviruses assemble at the endoplasmic reticulum-Golgi intermediate compartment (ERGIC), incorporating the S, M, E, and N proteins into new envelopes through budding into intracellular membranes, followed by exocytosis without immediate cell death.^[30] This non-lytic process allows sustained viral production and dissemination, though eventual cell damage occurs from accumulated viral burden.^[30] These mechanistic differences—non-enveloped endocytosis and lysis for rhinoviruses versus enveloped fusion and budding for coronaviruses—underlie variations in infection dynamics and host tissue impact during common cold episodes.^[29]^[30]

Host immune response

The host immune response to common cold viruses, primarily rhinoviruses, coronaviruses, and other respiratory pathogens, involves both innate and adaptive components that aim to limit viral replication while contributing to symptom manifestation. The innate immune system provides the first line of defense, rapidly detecting viral components through pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) on respiratory epithelial cells. Upon viral entry, these receptors recognize pathogen-associated molecular patterns like double-stranded RNA, triggering signaling pathways that induce the production of type I and type III interferons (IFN-α, IFN-β, and IFN-λ).^[31] These interferons establish an antiviral state in neighboring cells by upregulating genes for antiviral proteins and enhancing phagocytosis, thereby restricting viral spread in the upper respiratory tract.^[26] Concomitant with interferon production, epithelial cells and resident immune cells release pro-inflammatory cytokines, including interleukin-6 (IL-6) and interleukin-8 (IL-8), which mediate systemic symptoms such as fever and fatigue.^[32] IL-8, in particular, acts as a potent chemoattractant, recruiting neutrophils and macrophages to the site of infection.^[11] This inflammatory cascade leads to neutrophil infiltration and activation, resulting in the release of reactive oxygen species and proteases that help clear infected cells but also cause local tissue swelling and increased vascular permeability.^[31] Macrophages contribute by phagocytosing viral particles and secreting additional cytokines like tumor necrosis factor-α (TNF-α), further amplifying the response; however, this process promotes mucus hypersecretion and nasal congestion as protective barriers against further invasion.^[32] The adaptive immune response, while slower to activate, plays a supportive role in resolving the infection, though its impact is often limited by the short duration of common cold episodes (typically 7-10 days). CD4+ and CD8+ T cells infiltrate the airways, with CD8+ T cells directly lysing infected epithelial cells via perforin and granzymes, while CD4+ T cells produce interferon-γ to enhance antiviral activity.^[31] B cells are activated to produce virus-specific antibodies, including secretory IgA in mucosal secretions for immediate neutralization and IgG/IgM in serum for longer-term protection, appearing in approximately 80% of individuals within 7-21 days post-infection.^[11] Due to the transient nature of the infection and antigenic variability among cold viruses, adaptive immunity confers only partial and serotype-specific protection against reinfection.^[26] In rare severe cases, an exaggerated inflammatory response resembling a cytokine storm can occur, involving excessive release of IL-6, TNF-α, and other mediators, leading to heightened symptoms beyond typical mild illness; however, this is uncommon in immunocompetent individuals with common colds.^[31] Genetic variations in immune-related genes influence susceptibility and severity of common cold infections. For instance, rare loss-of-function mutations in the IFIH1 gene, which encodes the MDA5 helicase involved in recognizing viral RNA, impair innate antiviral signaling and markedly increase vulnerability to rhinoviruses, as observed in case studies of affected individuals.^[33] Additionally, polymorphisms in genes regulating interferon responses or cytokine production can modulate individual differences in symptom intensity and infection risk.^[34]

Diagnosis

Clinical assessment

The clinical assessment of the common cold primarily relies on a detailed patient history and physical examination to confirm the presence of typical upper respiratory symptoms and rule out more serious conditions. During history taking, clinicians inquire about the onset and duration of symptoms, which usually begin abruptly and last 7 to 10 days, along with potential exposure to ill contacts such as through close proximity in households, schools, or workplaces.^[10] Additional questions may cover risk factors like recent travel, smoking, or underlying comorbidities that could predispose to complications, as well as the progression of symptoms including any associated low-grade fever or malaise.^[35] The physical examination focuses on targeted evaluations to corroborate the history without requiring advanced testing in uncomplicated cases. Nasal inspection often reveals congestion, mucosal erythema, or clear rhinorrhea, while throat examination may show mild erythema or postnasal drip without significant exudate.^[10] Auscultation of the lungs typically yields clear breath sounds, and vital signs are assessed for normal temperature or only a low-grade fever under 38.5°C, with no tachycardia or hypotension.^[35] Neck palpation checks for tender cervical lymphadenopathy, which is usually minimal if present.^[36] Assessment also involves excluding red flags that suggest complications or alternative diagnoses beyond a simple cold. These include high fever exceeding 38.5°C for more than three days, shortness of breath, wheezing, intense sinus pain, or symptoms worsening after initial improvement, prompting further evaluation.^[2] In children, additional concerns are fever above 38°C lasting over two days, ear pain, or unusual irritability, which warrant prompt medical attention.^[2] In mild cases, self-diagnosis is generally reliable due to the familiar constellation of symptoms like runny nose and sore throat, and most individuals do not seek medical care unless symptoms persist beyond 10 days or intensify.^[3] Guidelines recommend consulting a healthcare provider if red flags appear or for vulnerable populations such as infants under three months or those with chronic conditions.^[37] For research purposes, validated scoring systems like the Wisconsin Upper Respiratory Symptom Survey (WURSS) quantify symptom severity and functional impact, assessing domains such as nasal symptoms, sore throat, cough, and quality-of-life effects over time, but these are not employed in routine clinical care.^[38] The WURSS-21, a short form, has demonstrated responsiveness in tracking cold progression in clinical trials involving hundreds of participants.^[38]

Differential diagnosis

The differential diagnosis of the common cold involves distinguishing its self-limited upper respiratory symptoms—such as rhinorrhea, nasal congestion, sneezing, and mild sore throat—from conditions with overlapping presentations to avoid misdiagnosis and ensure targeted evaluation. Common mimics include allergic and nonallergic rhinitis, influenza, bacterial pharyngitis, other viral respiratory infections like COVID-19, and non-infectious causes such as gastroesophageal reflux disease (GERD). Accurate differentiation often relies on symptom onset, associated features, and targeted testing, as symptoms like cough and congestion can persist or evolve in these alternatives.^[10]^[8] Allergic rhinitis typically presents with seasonal or perennial symptoms triggered by allergens, including intense nasal and ocular itching, clear rhinorrhea, and sneezing paroxysms, but lacks the fever, myalgias, or malaise seen in colds; symptoms often recur predictably with exposure and persist longer than the 7-10 days of a typical cold. Diagnosis is supported by a history of atopy and confirmed through skin prick testing or measurement of allergen-specific IgE levels, which are negative in viral colds.^[39]^[40]^[41] Influenza is characterized by abrupt onset within hours, high fever exceeding 101°F (38.3°C), prominent systemic symptoms like severe muscle aches, chills, headache, and profound fatigue, contrasting with the insidious progression and milder constitutional effects of the common cold. Confirmation involves rapid influenza diagnostic tests or reverse transcription-polymerase chain reaction (RT-PCR) assays, which detect influenza A or B viruses not associated with most colds.^[42]^[43] Bacterial pharyngitis, such as that caused by group A Streptococcus (strep throat), features acute sore throat with tender cervical lymphadenopathy, fever, headache, and tonsillar exudates or white patches, but notably spares cough, rhinorrhea, and conjunctivitis—hallmarks often present in viral colds. Diagnostic evaluation uses rapid antigen detection tests or throat culture to identify Streptococcus pyogenes, guiding antibiotic therapy absent in cold management.^[44]^[45]^[46] COVID-19 and other respiratory viruses overlap significantly with colds in causing cough, sore throat, nasal symptoms, and low-grade fever, but COVID-19 may include unique features like anosmia (loss of smell), dyspnea, or gastrointestinal upset, while viruses such as respiratory syncytial virus (RSV) or adenovirus can prolong symptoms or affect lower airways; epidemiological context, such as travel or outbreaks, aids suspicion. Differentiation requires nucleic acid amplification tests like RT-PCR for SARS-CoV-2 or multiplex panels for multiple pathogens, as antigen tests for colds are rarely indicated.^[47]^[48]^[10] Non-infectious mimics like vasomotor rhinitis produce chronic or episodic nasal congestion, rhinorrhea, and sneezing triggered by nonallergic irritants such as cold air, humidity changes, or odors, without fever or viral prodrome, and symptoms fluctuate with environmental exposure rather than resolving spontaneously. GERD-induced cough, conversely, manifests as a persistent, non-productive cough often worsening postprandially or nocturnally, isolated from upper respiratory signs, due to microaspiration of refluxed acid stimulating esophageal or laryngeal receptors. These are diagnosed by exclusion of infection via history and, for GERD, ambulatory pH monitoring or endoscopy, while vasomotor rhinitis responds to trigger avoidance without viral testing.^[49]^[50]^[51]

Prevention

Hygiene and behavioral measures

Hygiene and behavioral measures play a crucial role in reducing the transmission of the common cold, primarily through droplet and contact routes.^[1] These practices focus on interrupting the spread of respiratory viruses like rhinoviruses by minimizing direct and indirect contact with infectious particles. Frequent handwashing with soap and water for at least 20 seconds is one of the most effective ways to prevent the acquisition and spread of common cold viruses, as it removes germs from the hands and can reduce respiratory infections by approximately 20%.^[52] The process involves wetting hands with clean, running water (warm or cold), applying soap, lathering all surfaces including between fingers and under nails, scrubbing for 20 seconds, rinsing thoroughly, and drying with a clean towel or air dryer.^[53] Hands should be washed particularly after touching potentially contaminated surfaces, such as doorknobs or shared objects, and before touching the face. When soap and water are unavailable, using an alcohol-based hand sanitizer containing at least 60% alcohol provides an effective alternative for reducing common cold transmission by killing many germs on the hands.^[54] Apply enough sanitizer to cover all hand surfaces and rub until dry, which typically takes 20 seconds; this method helps avoid illness and limits germ spread in settings like public transport or workplaces.^[55] However, sanitizers are less effective against certain non-enveloped viruses and should not replace handwashing when hands are visibly dirty. Respiratory etiquette, such as covering the mouth and nose with a disposable tissue when coughing or sneezing, followed by immediate disposal of the tissue and handwashing, significantly limits the dispersal of infectious droplets that can transmit the common cold.^[56] If a tissue is unavailable, coughing or sneezing into the elbow or upper sleeve is recommended to avoid contaminating hands and nearby surfaces.^[57] This practice is especially important in crowded indoor environments where close contact increases transmission risk. Avoiding touching the eyes, nose, or mouth with unwashed hands prevents the introduction of cold viruses from contaminated surfaces directly into mucous membranes, a key entry point for infection.^[56] Similarly, refraining from sharing personal items like utensils, drinking glasses, towels, or cups reduces indirect contact transmission, as these objects can harbor viable viruses.^[58] Such measures are particularly relevant in household settings to curb spread among family members. Individuals experiencing common cold symptoms should isolate at home and away from others, including household members if possible, until symptoms improve and any fever has resolved without medication for at least 24 hours, thereby limiting community and household transmission.^[59] During this period, maintaining distance, improving ventilation, and using masks when interaction is unavoidable further support these efforts.^[59]

Immunization and environmental controls

No effective vaccine exists for the common cold primarily due to the high antigenic diversity of over 100 rhinovirus serotypes, the most common causative agents, which complicates broad-spectrum immunization efforts.^[60] Experimental approaches, such as multi-strain protein-based vaccines targeting multiple rhinovirus types, are under development; for instance, a candidate from Emory University has shown promise in preclinical studies by protecting monkeys against approximately one-third of known serotypes.^[60] As of 2025, these remain in early-stage trials and are not yet available for clinical use.^[61] Prophylactic antiviral medications are not standard for preventing common colds, even in high-risk groups, owing to the lack of approved agents with sufficient efficacy against rhinoviruses and other cold-causing viruses.^[62] In contrast, for influenza—a related respiratory illness—post-exposure prophylaxis with drugs like oseltamivir or baloxavir is recommended within 48 hours for vulnerable populations, such as the elderly or immunocompromised, to reduce infection risk by up to 70-90% in outbreak settings.^[63] Ongoing research into rhinovirus-specific antivirals, like vapendavir, focuses mainly on treatment rather than prevention, with phase II trials reporting positive results in May 2025, demonstrating benefits in reducing symptoms in COPD patients with rhinovirus infections.^[64] Environmental modifications play a key role in reducing common cold transmission by altering conditions that favor viral survival and spread. Maintaining indoor relative humidity between 40% and 60% may support mucosal health and reduce transmission of some respiratory viruses, though evidence for rhinoviruses is mixed and the effect is considered small by health authorities like the CDC compared to other measures such as improving ventilation and practicing good hygiene.^[65] Studies indicate that humidity levels between 40% and 60% are optimal for general respiratory health purposes.^[66] Improving ventilation in public spaces further aids prevention by diluting airborne viral loads. Installation of HEPA filters in HVAC systems or portable air purifiers in settings like schools and offices can capture up to 99.97% of particles 0.3 microns in size, including virus-laden droplets, thereby reducing transmission of common cold viruses.^[67] The U.S. Centers for Disease Control and Prevention recommends enhancing airflow and using such filtration as layered strategies to mitigate respiratory virus spread in congregate environments.^[68] Quarantine policies for common cold outbreaks draw from post-COVID-19 protocols, emphasizing isolation of symptomatic individuals to curb community transmission. Public health guidelines advise staying home and using precautions, such as masking when around others, for 5 days after symptoms begin to reduce transmission, as rhinoviruses remain contagious for up to 5-7 days or longer.^[59] In institutional outbreaks, such as in schools or long-term care facilities, targeted quarantine of exposed high-risk groups, combined with enhanced ventilation, helps contain spread without broad lockdowns.^[69]

Management

Symptomatic treatments

Symptomatic treatments for the common cold primarily involve non-pharmacological measures to alleviate discomfort and support recovery at home. Rest is essential, as it allows the body to direct energy toward fighting the viral infection, potentially shortening symptom duration. ^[37] Adequate hydration through drinking plenty of fluids, such as water, juice, or clear broths, helps thin mucus secretions, loosen congestion, and prevent dehydration exacerbated by fever or increased respiratory effort. ^[70] ^[71] Humidifying the air can ease nasal and throat congestion by moistening dry mucous membranes. Steam inhalation, such as from a hot shower or bowl of hot water, or the use of cool-mist humidifiers, adds moisture to indoor air, which may reduce coughing and improve breathing comfort during a cold. ^[72] Clean the humidifier daily to prevent bacterial growth, and aim for indoor humidity levels of 30-50% for optimal relief. ^[73] Saline nasal irrigation effectively clears nasal passages by flushing out excess mucus and irritants. Devices like neti pots or saline sprays deliver a saltwater solution to one nostril, allowing it to drain from the other, which can reduce congestion and sinus pressure associated with colds. ^[74] ^[75] Use distilled, sterile, or boiled-and-cooled water to avoid infection risks, and perform irrigation 1-2 times daily or as needed for symptom relief. ^[76] For sore throat relief, gargling with warm saltwater provides temporary soothing by reducing inflammation and loosening mucus in the throat. Mix about 1/4 to 1/2 teaspoon of salt in 8 ounces of warm water and gargle several times a day, especially after meals, to ease pain and discomfort. ^[77] ^[78] This simple remedy is safe for most adults and children over age 6. Over-the-counter expectorants like guaifenesin can help manage productive coughs by thinning and loosening chest mucus, making it easier to expel. It is particularly useful for wet coughs with phlegm during a cold, with typical adult dosing of 200-400 mg every 4 hours, not exceeding 2,400 mg per day, and should be taken with ample fluids to enhance effectiveness. ^[79] ^[80] Consult a healthcare provider before use in children under 12 or if symptoms persist beyond a week.

Pharmacological interventions

Pharmacological interventions for the common cold primarily target symptom relief, as no antiviral treatments cure the viral infection itself. Over-the-counter medications are commonly used to alleviate nasal congestion, pain, cough, and other discomforts, though evidence for their efficacy varies, and they do not shorten the overall duration of the illness. These interventions are most effective when selected based on specific symptoms, with careful consideration of potential side effects and contraindications, such as in patients with hypertension or cardiovascular risks. Decongestants like pseudoephedrine are oral agents that reduce nasal congestion by constricting blood vessels in the nasal mucosa, providing temporary relief in adults and older children. A Cochrane review of randomized trials found that multiple doses of oral pseudoephedrine may modestly improve subjective nasal congestion compared to placebo, with effects noticeable within hours but lasting only a few days. However, evidence is limited by small sample sizes and short-term studies, and pseudoephedrine is not recommended for children under 6 years due to insufficient safety data. Common side effects include insomnia, increased heart rate, and elevated blood pressure, with warnings for patients with hypertension or ischemic heart disease, as it can precipitate cardiovascular events.^[81]^[82]^[83] Antihistamines, such as loratadine, are sometimes used for symptoms like sneezing and runny nose, particularly if allergic components are suspected. Second-generation antihistamines like loratadine offer non-sedating relief by blocking histamine receptors, but a Cochrane systematic review of 10 trials concluded there is insufficient evidence to support their routine use for non-allergic common colds in adults or children, as they provide little benefit over placebo for overall symptom severity. They may be more helpful in combination with other agents for rhinorrhea, but monotherapy is generally ineffective for viral-induced symptoms. Side effects are minimal, including dry mouth or headache, but they are less suitable for dry cough or congestion-dominant colds.^[84]^[85] Analgesics including acetaminophen (paracetamol) and ibuprofen address headache, fever, sore throat, and myalgias associated with the common cold. Acetaminophen reduces fever and mild pain by inhibiting central prostaglandin synthesis, with one randomized trial showing it superior to placebo in decreasing rhinorrhea severity, though not for sneezing or coughing. Ibuprofen, a nonsteroidal anti-inflammatory drug, is more effective for fever-related discomfort and sore throat inflammation, as evidenced by comparative studies demonstrating greater antipyretic and analgesic effects than acetaminophen in upper respiratory infections. Both are safe in over-the-counter doses for short-term use, but acetaminophen risks hepatotoxicity with overdose, while ibuprofen may cause gastrointestinal upset or renal issues in vulnerable populations. A systematic review confirmed no significant differences in safety profiles among aspirin, acetaminophen, and ibuprofen for cold symptoms at recommended doses.^[86]^[87]^[88] Cough suppressants such as dextromethorphan are indicated for non-productive (dry) coughs, acting centrally to suppress the cough reflex without narcotic effects. A randomized controlled trial in adults demonstrated that dextromethorphan reduced objective cough frequency by 21% over 24 hours compared to placebo, with greater benefits during daytime. It is distinguished from expectorants like guaifenesin, which promote mucus clearance in productive coughs rather than suppressing the reflex; dextromethorphan is thus preferred for irritating, dry coughs but not for those with phlegm. Evidence in children is weaker, with some studies showing no superiority over placebo for acute cough severity. Side effects are rare but include dizziness or nausea at high doses.^[89]^[90]^[91] Antiviral agents have a limited role in common cold management, as most target specific viruses like rhinovirus but lack broad approval. Pleconaril, a capsid inhibitor specific to rhinoviruses and enteroviruses, showed promise in early phase III trials for reducing symptom duration by about one day, but the FDA declined approval in 2002 due to safety concerns, including interactions with oral contraceptives, and it remains unapproved for clinical use as of 2025, with ongoing research focused on analogues like vapendavir in experimental stages. No other antivirals are routinely recommended for uncomplicated colds. Antibiotics, such as amoxicillin, are ineffective against viral causes and should only be prescribed for confirmed secondary bacterial infections, like acute bacterial sinusitis or otitis media complicating the cold, as per guidelines emphasizing their role in preventing resistance. A Cochrane review of 11 trials confirmed antibiotics provide no benefit for typical cold symptoms and increase adverse effects like diarrhea.^[92]^[93]

Alternative and supportive therapies

Zinc lozenges have been investigated for their potential to shorten the duration of common cold symptoms when initiated early in the illness. A 2024 Cochrane systematic review of 34 randomized controlled trials involving 8,526 participants found that oral zinc, particularly in lozenge form at doses exceeding 75 mg/day, may reduce cold duration by approximately 2 days compared to placebo in some analyses, though results varied by formulation and timing, and the evidence remains inconclusive overall. However, the evidence remains mixed, with some meta-analyses reporting inconsistent benefits and potential side effects such as nausea, leading to cautious recommendations against routine use.^[94] Vitamin C supplementation is commonly used as a supportive therapy for colds, with research indicating modest effects on symptom severity rather than prevention. A 2023 meta-analysis showed that regular daily intake of 1 g or more reduced cold severity in individuals with severe symptoms. In 15 trials with 6,244 participants, regular supplementation of 1 g or more of vitamin C per day decreased the severity of colds by 15% in adults under physical stress, such as athletes or those in extreme environments, but offered no preventive benefit in the general population.^[95]^[96] Therapeutic doses started after symptom onset have not demonstrated significant reductions in duration or incidence, aligning with findings from updated reviews emphasizing limited overall efficacy. Herbal remedies like echinacea and elderberry are popular alternatives for alleviating cold symptoms, though systematic reviews highlight weak and inconsistent evidence for their benefits. For echinacea, a 2014 Cochrane review of 24 trials involving 4,631 participants concluded that various preparations showed little to no effect on preventing or treating colds compared to placebo, with any observed symptom relief likely attributable to methodological flaws in older studies. However, more recent meta-analyses as of 2024, including one of nine studies, indicate that echinacea may reduce cold duration, incidence of episodes, and antibiotic usage in upper respiratory tract infections, though high-quality evidence remains limited.^[97]^[98] Similarly, elderberry extracts have demonstrated potential in reducing symptom duration by 2-4 days in some randomized trials for influenza-like illnesses, but evidence specific to the common cold is limited, with a 2021 systematic review of eight studies noting insufficient high-quality data to support routine use and possible risks of immune overstimulation.^[99] Probiotics, often administered as supplements containing strains like Lactobacillus or Bifidobacterium, play an emerging role in supporting immune modulation during colds. A 2023 systematic review and meta-analysis of 12 randomized controlled trials found that probiotic use reduced the number of cold episodes by 47% and shortened illness duration by about one day in healthy adults, particularly when taken prophylactically.^[100] These effects are attributed to gut microbiota alterations that enhance mucosal immunity, though benefits are more pronounced in children and vary by strain, with ongoing research needed for optimal dosing. Acupuncture and homeopathy represent non-pharmacological supportive therapies for cold relief, but both lack robust evidence beyond placebo responses. A 2018 systematic review suggested possible reductions in common cold symptom severity and duration through mechanisms like improved local circulation, yet emphasized the need for larger placebo-controlled trials, as current data show inconsistent superiority over sham treatments.^[101] For homeopathy, a 2022 Cochrane review of 14 trials involving over 1,600 participants with acute respiratory infections, including colds, found no meaningful differences in recovery time or symptom resolution compared to placebo, attributing any perceived benefits to expectation effects.^[102]

Prognosis

Typical course and recovery

The common cold is a self-limiting illness, with the majority of cases resolving without specific medical intervention. In adults, symptoms typically last 7 to 10 days, while in children, the median duration is about 8 days, with 90% of cases resolving within 14 days.^[87] Overall, approximately 25% of episodes may extend to two weeks, but full recovery occurs in most individuals within this timeframe.^[103] Key recovery markers include the resolution of systemic symptoms early in the course, followed by the gradual subsidence of local upper respiratory symptoms. Fever, if present, usually abates by day 3, as prolonged fever beyond this point may warrant further evaluation.^[2] Nasal congestion and rhinorrhea often peak within the first 1 to 3 days and typically improve by days 7 to 10, though mild nasal symptoms can persist slightly longer in some cases.^[104] Cough, a common lingering symptom, may continue for up to 18 days in adults and three weeks in children due to postnasal drip and airway inflammation.^[3] Immunity following a common cold episode provides only short-term protection against the specific viral strain encountered, lasting weeks to months, but offers no lifelong or cross-strain immunity given the over 200 identified rhinovirus serotypes and other causative viruses.^[105] This transient response explains why reinfection with similar strains is possible, though the immune system may mount a faster secondary response upon re-exposure.^[106] Recurrence is common due to the diversity of circulating viruses, with adults experiencing an average of 2 to 3 episodes per year and children averaging 6 to 8, particularly preschoolers who may have up to 7 incidents annually.^[106] School-aged children face even higher rates, sometimes up to 12 episodes yearly, reflecting increased exposure in group settings.^[1] Monitoring for incomplete recovery is advisable if symptoms such as cough persist beyond three weeks, as this may indicate ongoing inflammation or require assessment to rule out secondary issues, though most cases still resolve spontaneously.^[3] Individuals should track symptom progression and seek medical advice if recovery deviates from the expected timeline.^[37]

Potential complications

While the common cold is typically self-limiting, it can lead to secondary bacterial infections in a minority of cases, particularly when viral inflammation impairs local defenses in the upper or lower respiratory tract. These infections arise as opportunistic bacterial overgrowth following the initial viral insult, with acute otitis media being one of the most frequent, occurring in approximately 5% of preschool-aged children during or shortly after a cold episode.^[8] Sinusitis may develop if nasal symptoms persist beyond 10 days, signaling bacterial involvement in about 0.5-2% of adult cases, while bacterial pneumonia remains uncommon, affecting less than 1% of otherwise healthy individuals but rising in those with predisposing factors.^[107]^[108] In individuals with underlying respiratory conditions, the common cold can exacerbate chronic diseases through heightened airway inflammation and hyperresponsiveness. Rhinovirus, the predominant cause of colds, frequently triggers asthma flares, with viral detection in up to 80% of acute exacerbations in children and adults, leading to worsened wheezing, shortness of breath, and increased medication needs.^[109] Similarly, in chronic obstructive pulmonary disease (COPD), cold-like symptoms precede about 35% of exacerbations, amplifying cough, sputum production, and dyspnea due to impaired mucociliary clearance and bacterial colonization.^[110] Rare systemic complications, such as myocarditis, are exceptionally uncommon with typical common cold viruses like rhinoviruses but have been documented in isolated cases, where viral infection may inflame cardiac tissue, potentially leading to arrhythmias or heart failure.^[111] Post-viral effects, including persistent olfactory dysfunction (anosmia or hyposmia), can occur following upper respiratory infections, with most individuals recovering fully though a small proportion may experience prolonged symptoms even months later, as noted in studies heightened by post-2020 awareness of viral impacts on sensory nerves.^[112] Post-viral fatigue, though less specifically tied to common colds, can manifest as prolonged malaise in susceptible cases, mirroring broader viral sequelae. Overall complication rates remain low, under 5% in healthy populations, but risk escalates at age extremes—children under 5 and adults over 65 face higher odds due to immature or waning immunity—and with smoking, which doubles infection susceptibility by damaging epithelial barriers and suppressing ciliary function.^[26]^[113]

Epidemiology

Global prevalence and distribution

The common cold represents a substantial global health burden, primarily manifesting as upper respiratory infections (URIs) that are predominantly mild and viral in origin. According to the Global Burden of Disease Study 2021, there were approximately 17.2 billion new episodes of URIs worldwide in 2021, encompassing the vast majority of common cold cases across all age groups and sexes.^[114] In the United States, acute URIs, including common colds, result in approximately 1 billion episodes annually, reflecting the disease's high incidence in developed settings with robust reporting.^[115] These figures underscore the common cold's ubiquity, with adults typically experiencing 2–4 episodes per year and children up to 6–8, driven by over 200 circulating respiratory viruses.^[26] Geographically, the prevalence exhibits distinct patterns influenced by climate. In temperate regions, the burden is highest during colder months, with year-round occurrence but marked seasonal peaks that align with increased indoor crowding and lower humidity favoring viral survival.^[116] In contrast, tropical and subtropical areas experience more consistent year-round transmission, often intensifying during rainy seasons due to heightened humidity and behavioral factors like sheltering.^[117] Overall incidence rates have shown a gradual decline globally since 1990, with age-standardized rates dropping by about 7.6% by 2021, potentially attributable to improved public health measures and socioeconomic advancements.^[114] Underreporting poses a major challenge to accurate assessment, as the self-limiting nature of the common cold results in most cases resolving without medical consultation. Data gaps are particularly pronounced in low-income regions, where limited surveillance infrastructure leads to underestimation of incidence, as highlighted in Global Burden of Disease analyses that rely on modeled extrapolations for under-resourced areas.^[118] Disparities in burden are evident, with higher rates in urban versus rural settings due to greater population density facilitating transmission, though rural low-income areas may face elevated risks from poorer access to preventive care.^[118]

Seasonal and demographic patterns

In temperate zones, the common cold exhibits a marked winter predominance, with incidence peaking from late fall through early spring. This pattern is attributed to increased indoor crowding during colder months, which facilitates close-contact transmission among household members and in public spaces, as well as reduced relative humidity from indoor heating, which prolongs the survival and aerosol stability of rhinoviruses, the primary causative agents.^[119]^[120] Low outdoor temperatures further contribute by driving people indoors, amplifying these effects in regions like North America and Europe.^[121] Some temperate regions display bimodal peaks in common cold incidence, with a major surge in early fall (September–November) and a secondary rise in late winter or early spring (February–April). These patterns align closely with school calendars, as the return of children to classrooms in fall introduces viruses into communities, while spring peaks may reflect waning immunity and renewed gatherings before summer breaks; studies in school districts have shown sharp declines in respiratory illness cases immediately following winter and spring vacations.^[122]^[123] Rhinovirus detections, in particular, follow this dual-peak distribution, underscoring the role of pediatric populations in seasonal dynamics.^[124] Demographic variations in common cold incidence are pronounced by age. Children, especially those aged 1–5 years, experience the highest rates, averaging 6–10 episodes per year, due to immature immunity and frequent exposure in daycare or school settings.^[125]^[126] Adults typically suffer 2–4 colds annually, reflecting greater immune experience but ongoing community exposure through work and travel.^[11] In contrast, elderly individuals (over 65 years) report fewer infections—often 1–2 per year—owing to reduced social contacts and prior exposures, though infections tend to be more severe, with prolonged symptoms and higher risks of complications like pneumonia due to age-related immune senescence.^[26]^[127] Gender differences in incidence are modest but notable, with women, particularly those aged 20–30 years, experiencing slightly higher rates than men, potentially linked to greater exposure from childcare responsibilities.^[128] Men may exhibit more pronounced symptoms during infections, possibly due to differences in immune response modulation, though overall attack rates remain comparable across genders in most populations.^[129] Geographic variations highlight the influence of latitude on seasonality. In equatorial and tropical regions, common cold incidence remains relatively constant year-round, with minimal peaks tied to rainy seasons rather than temperature drops, as consistent warmth and humidity support steady viral circulation without the indoor confinement seen elsewhere.^[130] In polar and high-latitude areas, seasonality is even more extreme than in temperate zones, with intense winter outbreaks driven by prolonged darkness, extreme cold, and isolated communities, though overall incidence may be lower due to smaller population densities.^[27] As of 2025, climate change is beginning to modulate these patterns, with warming temperatures potentially extending transmission windows in temperate and polar regions by reducing cold-induced behavioral changes like indoor crowding, while increasing humidity variability could enhance viral stability in unexpected seasons.^[131] These shifts underscore the need for adaptive public health strategies in affected demographics.^[132]

History

Early recognition and virology

The earliest descriptions of symptoms resembling the common cold date back to the 5th century BCE, when the Greek physician Hippocrates documented "catarrh" as an acute inflammation of the upper respiratory tract characterized by nasal discharge, sneezing, and cough, attributing it to an imbalance in the body's humors—specifically, an excess of cold and moist phlegm triggered by chilling of the body.^[133] This humoral theory dominated ancient and medieval understandings, with Roman physician Pedanius Dioscorides around 60 CE recommending remedies like chicken soup to alleviate symptoms by warming the body and expelling excess fluids.^[133] Pre-20th century misconceptions widely held that exposure to cold weather, drafts, or dampness directly caused colds by allowing "cold air" to penetrate the body and disrupt internal balance, a belief echoed in folk remedies such as hot toddies, bloodletting, and herbal infusions to "sweat out" the illness, despite no evidence linking temperature to disease onset.^[26]^[133] In the 19th century, efforts to study the contagious nature of the common cold were severely limited by the absence of germ theory, which was not firmly established until the late 1800s through work by Louis Pasteur and Robert Koch on bacterial pathogens. Physicians like those described in late-1800s medical literature investigated "catarrh" through observation and rudimentary epidemiology, noting patterns of spread in crowded settings but attributing transmission to miasmas—foul vapors from decaying matter—rather than invisible agents.^[134] Early suggestions of infectiousness emerged in the 1890s as bacteriological methods advanced, but attempts to isolate a causative microbe failed, as viruses were unknown and tools like tissue culture were unavailable, perpetuating views of colds as primarily environmental or constitutional disorders.^[135] The viral etiology of the common cold began to unfold in the 1950s with the first successful isolations of rhinoviruses, the primary causative agents, using newly developed human tissue culture techniques. In 1953, American virologist Winston H. Price isolated an agent from nasal secretions of ill nurses at Johns Hopkins University, initially culturing it in human embryonic lung cells and later confirming its role in mild respiratory illness.^[136] Independent efforts in 1956 by U.S. and U.K. research groups, including the Medical Research Council's Common Cold Unit led by David Tyrrell, isolated similar picornaviruses from volunteers exposed to filtered nasal washings, establishing rhinoviruses as filterable agents distinct from bacteria and capable of producing cold-like symptoms in human challenge studies.^[136]^[133] From the 1960s through the 1980s, intensive serological and antigenic studies identified over 100 distinct rhinovirus serotypes, revealing the virus family's extensive diversity and complicating efforts to pinpoint a single cause for the common cold. Early classifications in the 1960s by researchers like Taylor-Robinson and Tyrrell distinguished initial strains based on neutralization assays, while by the 1970s, approximately 90 serotypes had been cataloged through cross-neutralization tests using reference antisera.^[136] By the 1980s, advanced techniques such as partial genome sequencing divided these into major groups—HRV-A with 74 serotypes and HRV-B with 25—highlighting antigenic variation that enables repeated infections and underscoring rhinoviruses' role in over half of common cold cases, alongside other viruses like coronaviruses.^[136]12162-9/fulltext)

Treatment evolution

In the early 20th century, management of the common cold relied heavily on patent medicines, which were proprietary remedies marketed aggressively for respiratory symptoms but often proven ineffective and sometimes harmful due to unregulated ingredients like opiates or alcohol.^[137] These tonics and elixirs promised cures but lacked empirical support, leading to widespread consumer skepticism by the 1910s amid Pure Food and Drug Act reforms.^[138] Concurrently, the introduction of aspirin (acetylsalicylic acid) in 1899 by Bayer marked a significant advancement, offering reliable symptomatic relief for fever, headache, and body aches associated with colds through its anti-inflammatory and analgesic properties.^[139] By the 1910s, aspirin had become a staple over-the-counter option, reducing reliance on unproven remedies and setting the stage for evidence-based symptom management.^[140] By the mid-20th century, the identification of viruses like rhinovirus in 1956 shifted treatment paradigms toward supportive care, emphasizing rest, hydration, and analgesics over curative interventions.^[141] This era saw the rejection of antibiotics for common colds, as clinical evidence established their ineffectiveness against viral pathogens and highlighted risks like resistance and side effects.^[142] Physicians increasingly advocated symptomatic relief with aspirin or emerging antihistamines, while public health campaigns discouraged antibiotic overuse for self-limiting respiratory infections.^[143] From the 1980s to the 2000s, over-the-counter decongestants such as pseudoephedrine and phenylephrine proliferated, driven by consumer demand for rapid nasal congestion relief and regulatory approvals under the FDA's OTC monograph system established in 1972.^[144] These oral agents, often combined with antihistamines in multi-symptom formulas, became market staples, though evidence of their efficacy varied.^[145] Simultaneously, zinc trials emerged, with the first randomized controlled study in 1984 testing zinc gluconate lozenges, reporting reduced cold duration, though subsequent research yielded mixed results on dosing and formulation.^[146] By the 1990s, intranasal zinc sprays entered trials, but concerns over anosmia led to their market withdrawal in 2009.^[147] In the 2010s, Cochrane systematic reviews synthesized evidence on cold treatments, concluding limited benefits from zinc (shortening symptoms by about one day when started early) and vitamin C (modest preventive effects in high-risk groups), while reinforcing symptomatic care as the cornerstone. These guidelines influenced clinical practice, prioritizing non-pharmacologic measures like saline irrigation over unproven remedies. The COVID-19 pandemic from 2020 onward heightened focus on antiviral strategies for respiratory viruses, including coronaviruses that cause some colds, spurring interest in broad-spectrum agents despite challenges in targeting the diverse cold etiologies.^[148] Regulatory milestones shaped treatment availability, including FDA approvals for OTC cold products in the 1970s-1980s and withdrawals like phenylpropanolamine in 2000 due to stroke risks.^[149] As of 2025, ongoing debates surround oral phenylephrine, with the FDA proposing its removal from OTC monographs in November 2024 after advisory panels deemed it no more effective than placebo for nasal decongestion, prompting industry challenges and reformulations.^[150] This evolution underscores a progression from unverified cures to evidence-driven, regulatory-vetted symptomatic management.

Research directions

Emerging antiviral therapies

Recent research into direct-acting antivirals for common cold viruses, primarily rhinoviruses, has focused on compounds that inhibit key stages of viral replication, such as capsid assembly and RNA synthesis, to address the limitations of symptomatic treatments. Capsid inhibitors, which bind to the viral capsid to prevent uncoating and genome release, represent a longstanding but revitalized approach. Pleconaril, an oral capsid-binding agent targeting the VP1 protein, demonstrated efficacy in Phase II trials by reducing viral RNA levels, culture positivity, and illness duration by approximately one day in adults with rhinovirus infections.^[151] Although Phase III trials were halted in 2002 due to concerns over modest efficacy, safety issues like cytochrome P-450 interactions, and resistance emergence in up to 10.7% of isolates, interest has revived post-2020 with preclinical studies on pleconaril analogues showing improved potency against diverse serotypes and potential for repurposing in respiratory picornavirus infections.^[152] Vapendavir, another capsid inhibitor active against all major rhinovirus families (A, B, and C), has advanced to Phase II clinical trials, particularly for rhinovirus-triggered exacerbations in vulnerable populations like those with COPD. In a 2025 placebo-controlled challenge study involving COPD patients, vapendavir (264 mg or 529 mg doses) reduced viral load, improved patient-reported upper and lower respiratory symptoms, and shortened the overall illness course compared to placebo, with benefits including maintained lung function and consistent symptom relief across serotypes.^[153]^[64] These results suggest a 20-30% reduction in symptom severity metrics, though larger trials are needed to confirm broad applicability to uncomplicated common colds.^[154] Efforts to develop RNA polymerase inhibitors aim for broad-spectrum activity against rhinoviruses and related coronaviruses by targeting the viral RNA-dependent RNA polymerase (RdRp, or 3Dpol), which lacks proofreading and is essential for genome replication. Compounds like molnupiravir (EIDD-2801), a nucleoside analogue, exhibit potent in vitro and in vivo inhibition of picornavirus RdRp, reducing viral titers in cell models of rhinovirus infection while also showing efficacy against SARS-CoV-2.^[152] Similarly, gemcitabine, repurposed from oncology, inhibits rhinovirus RNA synthesis at sub-cytotoxic doses and displays activity against hard-to-treat HRV-C strains, highlighting its potential as a pan-picornavirus agent.^[151] Azvudine, approved in China for COVID-19, targets RdRp in enteroviruses and rhinoviruses, with preclinical data supporting its expansion to common cold viruses.^[152] A major challenge in developing these antivirals is the serotype diversity of rhinoviruses, with over 160 genotypes across species A, B, and C, which leads to variable drug susceptibility and rapid resistance emergence, necessitating pan-viral agents that target conserved replication machinery.^[155] For instance, capsid inhibitors like pleconaril and vapendavir show reduced efficacy against certain HRV-C variants due to structural variability in the VP1 pocket.^[151] Broad-spectrum RdRp inhibitors address this by exploiting shared enzymatic features across picornaviruses and coronaviruses, but clinical translation remains limited by delivery to upper airways and potential host toxicity.^[152] Advancements in animal models have bolstered preclinical evaluation of these therapies, with ferrets emerging as a valuable system due to their physiological similarity to humans in respiratory virus pathogenesis and transmission. Ferret studies of capsid and polymerase inhibitors, including pleconaril analogues, have demonstrated reduced viral shedding and symptom severity in rhinovirus-challenge models, providing translational insights beyond traditional mouse or cotton rat systems.^[152] These models have informed 2025 trial designs, emphasizing endpoints like viral load reduction and immune priming.^[156]

Vaccine development efforts

Efforts to develop vaccines against the common cold, primarily targeting rhinoviruses which cause the majority of cases, have faced significant hurdles due to the virus's antigenic diversity. In the 1960s and early 1970s, researchers conducted clinical trials with monovalent formalin-inactivated rhinovirus vaccines, such as those using a single serotype like RV13, administered via subcutaneous or intranasal routes. These vaccines induced only minimal protection against homologous strains and failed to provide cross-protection against heterologous serotypes. Multivalent formulations covering up to 10 serotypes were also tested but similarly proved ineffective, as inactivation processes destroyed key neutralizing epitopes on the viral capsid, and the absence of effective adjuvants limited immune responses. The primary reason for these historical failures was the extensive serotypic variation among over 100 rhinovirus types, which precluded broad immunity from limited-valency approaches.^[157]^[158] Contemporary vaccine strategies have shifted toward multi-epitope designs to address rhinovirus diversity, drawing inspiration from platforms successful in COVID-19 vaccine development. Virus-like particles (VLPs), which mimic viral structure without genetic material, are being explored as a safe alternative to inactivated viruses, similar to their use in human papillomavirus vaccines, to elicit robust antibody responses against conserved capsid regions like VP1 and VP4. Messenger RNA (mRNA) platforms, accelerated by COVID-19 technologies, are under preclinical investigation to encode multiple rhinovirus epitopes, enabling rapid production and potentially stronger cellular immunity. Subunit vaccines targeting conserved peptides from VP0, VP1, and VP4 have shown promise in animal models, inducing cross-serotype neutralizing antibodies and T-cell responses that reduce viral loads in cotton rats and transgenic mice. These approaches aim to overcome serotype barriers by focusing on shared antigenic sites rather than individual strains.^[157]^[159]^[160] As of 2025, no rhinovirus vaccine has reached licensure, but preclinical advancements indicate growing momentum. A polyvalent inactivated vaccine covering 50 rhinovirus-A serotypes elicited neutralizing antibodies against 49 of them in rhesus macaques, demonstrating partial cross-protection in vivo. Early human trials, such as one led by researchers at Imperial College London evaluating undisclosed multi-serotype candidates, have reported initial safety data supporting progression toward broader efficacy testing. These efforts target at least 50% efficacy against prevalent strains, though challenges like antigenic drift and the need for annual updates persist. Correlates of protection remain centered on serum neutralizing antibodies, which block viral entry via the ICAM-1 receptor, but their short-lived nature—waning within months—necessitates boosters or T-cell-focused enhancements for durable immunity. In January 2025, scientists at the University of Hong Kong successfully cultured previously uncultivable human rhinovirus C (HRV-C) strains, a breakthrough that enhances understanding of these viruses and accelerates vaccine and antiviral development. Additionally, at the 2025 American Thoracic Society conference, preclinical data on APL-10456, an adjuvanted rhinovirus vaccine candidate, demonstrated immunogenicity against multiple serotypes in animal models, paving the way for potential clinical advancement.^[159]^[60]^[161]^[162]^[163] Ethical considerations in common cold vaccine development highlight tensions between potential benefits and resource allocation. The mild, self-limiting nature of the disease raises questions about justifying high development costs—estimated in billions—against more severe threats like influenza or emerging pathogens, despite the common cold's substantial economic burden from lost productivity. Prioritizing such vaccines could divert funding from higher-mortality diseases, prompting debates on equitable global health investment. Additionally, conducting challenge trials in healthy volunteers poses risks of inducing illness for marginal personal gain, underscoring the need for stringent informed consent and oversight to balance scientific progress with participant welfare.^[60]^[164]^[165]

Societal impact

Public health burden

The common cold places considerable strain on healthcare systems worldwide, primarily through frequent ambulatory care visits for symptoms of upper respiratory infections. In the United States alone, these infections account for approximately 100-120 million doctor visits annually, overwhelming primary care and urgent care facilities during peak seasons.^[166] This burden extends to significant absenteeism, with the common cold causing an estimated 25 million missed workdays directly, plus over 126 million from parents staying home to care for ill children, and 22-23 million missed school days each year in the US, contributing to broader global disruptions estimated at hundreds of millions such days annually.^[167]^[168]^[128] A major public health concern is the overuse of antibiotics for viral colds, which are ineffective against the causative viruses; around 30% of outpatient antibiotic prescriptions in the US are inappropriate for such respiratory conditions, exacerbating antimicrobial resistance and unnecessary healthcare costs.^[169] The burden intensifies during overlapping respiratory virus seasons, as co-circulation of influenza, COVID-19, and RSV with common cold viruses leads to higher combined hospitalization demands and diagnostic challenges, according to 2025 CDC assessments predicting similar or elevated peak activity levels.^[170]^[171] Public health strategies increasingly integrate co-prevention measures into existing vaccination programs for influenza and COVID-19, promoting hygiene education and multilayered interventions to mitigate the overall impact of multiple respiratory pathogens, including rhinoviruses responsible for most colds.^[172]

Economic and productivity effects

The common cold imposes substantial direct economic costs in the United States, estimated at $17 billion annually in the early 2000s for physician visits, medications, and treatment of secondary infections, which, adjusted for medical inflation, equates to approximately $30-35 billion in 2025 dollars.^[173]^[174] These costs reflect over 100 million annual healthcare encounters, including outpatient visits and over-the-counter remedies, with expenditures remaining elevated despite post-COVID shifts in healthcare utilization.^[175] Indirect costs from productivity losses are even more pronounced, with the common cold leading to roughly 150 million lost workdays annually in the US, including 22-25 million from adult absenteeism and over 126 million from parents staying home to care for ill children, translating to $20-25 billion in foregone wages and reduced output.^[176]^[175]^[167] Globally, these figures scale significantly, potentially exceeding hundreds of millions of workdays when extrapolated across economies, though precise international data vary due to differing labor markets and reporting.^[177] In 2025, remote work trends post-COVID have modestly mitigated transmission and absenteeism in office-based roles, reducing overall estimates by 10-20% in hybrid sectors, but costs persist at $25 billion for US productivity losses alone, with studies showing declined sickness absenteeism among teleworkers.^[177]^[178]^[179] Industry-specific impacts are notable, with service sectors experiencing higher absenteeism rates in personal care and customer service occupations due to close-contact environments that facilitate spread, amplifying disruptions in hospitality and retail.^[180] Childcare-related absences add further strain, as parental work loss often incurs additional expenses for alternative care or lost income, particularly affecting working families in dual-income households.^[181] Prevention strategies, such as hygiene campaigns promoting handwashing, offer significant cost-benefit potential, reducing acute respiratory infections by 10-20% and yielding savings of up to $3-5 per dollar invested through fewer infections and productivity gains.^[182]^[183] These interventions, when implemented in workplaces and communities, can offset a portion of the annual burden, particularly in high-contact settings.^[184]

References

[1]
About Common Cold - CDC
Oct 15, 2024 · A cold is a viral infection of the upper respiratory tract (also called an upper respiratory infection or URI). Colds usually last less than a week.
[2]
Common cold - Symptoms and causes - Mayo Clinic
May 24, 2023 · Symptoms · Runny or stuffy nose. · Sore or scratchy throat. · Cough. · Sneezing. · Generally feeling unwell. · Slight body aches or a mild headache.
[3]
Overview: Common colds - InformedHealth.org - NCBI Bookshelf
Dec 11, 2023 · At a glance · The typical symptoms of a cold are a cough, a stuffy nose and a sore throat. · Colds are caused by a harmless viral infection.Introduction · Symptoms · Outlook · Diagnosis
[4]
Mechanisms of symptoms of common cold and flu - PMC
It is the familiar symptoms of sore throat, runny nose, sneezing, and nasal congestion, muscle aches, chilliness and fever, etc., that define the common ...
[5]
Common cold - Frontiers
Jun 21, 2023 · Mechanism of symptoms of common cold. Viral infection of the upper respiratory tract triggers a local immune innate response in the infected ...Definition of common cold · Mechanism of symptoms of... · Morbidity of common cold
[6]
Common Cold (Rhinovirus): Symptoms, Causes & Treatment
Adults don't usually get a fever with a common cold, although kids sometimes do. The flu also causes body aches and more severe symptoms than a cold.
[7]
Understanding the symptoms of the common cold and influenza - PMC
The early symptoms were headache, sneezing, chilliness, and malaise, which developed quickly and also declined rapidly after 1–2 days, whereas the later ...
[8]
The Common Cold - PMC - PubMed Central - NIH
The common cold, also known as upper respiratory tract infection (URI), is an acute, self-limited viral infection of the upper airway that also may involve the ...Etiology · Epidemiology · Figure 26.1Missing: overview | Show results with:overview<|control11|><|separator|>
[9]
Viruses and Bacteria in the Etiology of the Common Cold - PMC - NIH
Rhinoviruses have been recently estimated to cause 34% of all respiratory illnesses (23). With the exception of coronaviruses, the proportion of other ...
[10]
Upper Respiratory Tract Infections With Focus on The Common Cold
May 4, 2025 · The common cold is a syndrome that manifests as a mild-to-moderate, self-limited URTI, characterized by inflammation that causes malaise, nasal ...Upper Respiratory Tract... · Etiology · History And Physical
[11]
Rhinovirus (RV) Infection (Common Cold) - Medscape Reference
Aug 18, 2023 · Rhinoviruses (RVs) are the most common cause of the common cold. They chiefly cause upper respiratory tract infections (URTIs) but may infect the lower ...
[12]
Facts About the Common Cold | American Lung Association
30‏/10‏/2024 · Children suffer from more colds per year than adults. Colds are ... Young children can have acetaminophen or ibuprofen for fever. Be ...
[13]
Enveloped vs. non-enveloped viruses - virology research services
May 22, 2022 · Non-enveloped viruses are more resistant to extreme pH, heat, dryness, and simple disinfectants. Some examples of non-enveloped viruses are ...
[14]
COVID-19, cold, allergies and the flu: What are the differences?
Both COVID-19 and the common cold are caused by viruses. COVID-19 is caused by SARS-CoV-2. The common cold most often is caused by rhinoviruses. All of these ...Missing: prevalence | Show results with:prevalence
[15]
The mystery of why Covid-19 seems to be becoming milder - BBC
Jan 14, 2025 · Some indications suggest that Covid in 2025 is a milder disease. The once common symptoms of loss of taste and smell are becoming less common.
[16]
Transmission of colds - PMC - NIH
Rhinovirus has been shown to infect via self-inoculation following hand-to-hand contact with contaminated hands or hand-to-surface contact with contaminated ...
[17]
Update on Human Rhinovirus and Coronavirus Infections - PMC - NIH
School-aged children frequently introduce HRV infections into the home. Secondary attack rates range from 25 to 70%. Day-care centers and schools are also ...
[18]
Effects of Exercise on Immune Function - Gatorade Sports Science ...
Other factors such as psychological stress, lack of sleep and malnutrition can also depress immunity and lead to increased risk of infection. Periods of ...Key Points · Exercise, Immunity And... · Practical Applications
[19]
Effects of Malnutrition on the Immune System and Infection and ... - NIH
Dec 19, 2023 · Immune Systems of Malnourished Children. 3.1. Undernourishment. 3.1.1. Vitamins and Minerals. Childhood malnutrition affects innate and adaptive ...
[20]
In China, Students in Crowded Dormitories with a Low Ventilation ...
Crowded dormitories with low out-to indoor airflow rates are associated with more respiratory infections among college students.
[21]
Ventilation and Respiratory Viruses | US EPA
Sep 8, 2025 · Avoid ventilation with outdoor air when outdoor air pollution or humidity are high or during extreme outdoor conditions. Check AirNow for ...Missing: crowded | Show results with:crowded
[22]
Association between indoor environment and common cold among ...
The main symptoms, duration, and prevalence of a common cold in children are significantly influenced by indoor temperature, relative humidity, formaldehyde, ...
[23]
Evolution of the immune system in humans from infancy to old age
Dec 22, 2015 · Yet the immune system is relatively immature at birth and has to evolve during a life of exposure to multiple foreign challenges through ...
[24]
Cold | Boston Children's Hospital
Who is at increased risk of catching the common cold? Children suffer more colds each year than adults, due to their immature immune systems and to the ...
[25]
Vulnerability for Respiratory Infections in Asthma Patients - NIH
Sep 6, 2022 · It focuses on the evidence to suggest that people with asthma are at increased risk of viral infection, and viral infections in turn are known ...
[26]
Common cold - PMC - NIH
Jun 22, 2023 · The common cold is a unique human disease, as it is arguably the most common disease and because of the large number of respiratory viruses causing colds
[27]
Susceptibility to the common cold virus is associated with day length
Aug 19, 2022 · Seasonal rhythms regulate reproductive, metabolic, behavioral, and immune function in animals at temperate clines, and this action across ...
[28]
Seasonal immune modulation in humans: Observed patterns and ...
Seasonal variation in immunity appears to occur in humans, and it is plausible that this variation may contribute to the seasonality of respiratory infections.
[29]
The human rhinovirus: human‐pathological impact, mechanisms of ...
As the major etiological agent of the common cold, human rhinoviruses (HRV) cause millions of lost working and school days annually.
[30]
Coronaviruses: An Overview of Their Replication and Pathogenesis
Attachment and Entry The S-protein–receptor interaction is the primary determinant for a coronavirus to infect a host species and also governs the tissue ...Missing: cold | Show results with:cold
[31]
The host immune response in respiratory virus infection
In this review, we highlight major components of the host response to acute viral infection and their role in contributing to mitigating respiratory damage.
[32]
Host immune responses to rhinovirus: Mechanisms in asthma - PMC
Many airway cell types are involved in the immune response to rhinovirus, but most important are respiratory epithelial cells and possibly macrophages.
[33]
Scientists Discover Rare Genetic Susceptibility to Common Cold
Jun 30, 2017 · Scientists have identified a rare genetic mutation that results in a markedly increased susceptibility to infection by human rhinoviruses ...Missing: variations | Show results with:variations
[34]
Host Genetic Variation Influences Gene Expression Response to ...
In this study, we explored whether host genetic variation is associated with variation in gene expression response to RV infections between individuals.
[35]
Common cold - Diagnosis Approach - BMJ Best Practice
A brief physical examination, including temperature, pulse and blood pressure, and examination of oropharynx, nares, neck, and chest.
[36]
Common Cold - Infectious Diseases - Merck Manuals
The common cold is an acute, usually afebrile, self-limited viral infection causing upper respiratory symptoms, such as rhinorrhea, cough, and sore throat.
[37]
Common cold - Diagnosis and treatment - Mayo Clinic
May 24, 2023 · There's no cure for the common cold. Most cases of the common cold get better without treatment within 7 to 10 days. But a cough may last a few more days.Missing: progression | Show results with:progression
[38]
Wisconsin Upper Respiratory Symptom Survey (WURSS)
Feb 12, 2025 · Acute respiratory infection (ARI), including the common cold and influenza, is the most prevalent of human illnesses. Surveys report that over ...
[39]
Cold or allergy: Which is it? - Mayo Clinic
Feb 13, 2024 · You can tell the difference between a cold and a seasonal allergy by key symptoms and how regularly symptoms appear.Missing: differential | Show results with:differential
[40]
Colds, Allergies and Sinusitis — How to Tell the Difference
Colds and allergies can both lead to sinusitis which occurs when the sinuses become swollen and blocks mucous from draining, leading to painful pressure and ...Missing: differential | Show results with:differential
[41]
Allergic Rhinitis - StatPearls - NCBI Bookshelf
Differential Diagnosis · Vasomotor rhinitis - noninflammatory rhinitis that can be triggered by a change in temperature, odors, or humidity · Infectious rhinitis ...
[42]
Cold Versus Flu | Influenza (Flu) - CDC
Aug 8, 2024 · Cold symptoms are usually milder than the symptoms of flu. People with colds are more likely to have a runny or stuffy nose. Colds generally do ...
[43]
Is it a cold or flu? | Flu Resource Center - CDC
Aug 13, 2024 · The signs and symptoms of colds can include a gradual onset of symptoms, fevers are rare, slight aches, chills are uncommon, sometimes fatigue ...
[44]
Sore Throat Basics - CDC
Apr 17, 2024 · Sore throat can be a symptom of strep throat, the common cold, allergies or other upper respiratory tract illness. Most sore throats will get better on their ...
[45]
Pharyngitis - StatPearls - NCBI Bookshelf - NIH
The most common bacterial infection is Group A beta-hemolytic streptococci, which causes 5% to 36% of cases of acute pharyngitis.
[46]
Bacterial Pharyngitis - StatPearls - NCBI Bookshelf - NIH
Oct 6, 2024 · Pharyngitis, characterized by inflammation of the pharynx leading to a sore throat, often stems from noninfectious causes or viral respiratory pathogens.
[47]
Similarities and Differences between Flu and COVID-19 - CDC
Sep 17, 2024 · Influenza (flu) and COVID-19 are both contagious respiratory illnesses, but they are caused by different viruses.
[48]
Similarities and differences between COVID-19 and Influenza
Oct 14, 2024 · In many cases COVID-19 and influenza cause similar symptoms, including cough, runny nose, sore throat, fever, headache and fatigue.
[49]
Nonallergic rhinitis - Symptoms & causes - Mayo Clinic
Mar 14, 2023 · Nonallergic rhinitis involves sneezing or a stuffy, drippy nose. It can be a long-term problem, and it has no clear cause.Overview · Causes · Complications<|separator|>
[50]
Vasomotor Rhinitis - StatPearls - NCBI Bookshelf
Vasomotor rhinitis is a term often used to describe rhinitis symptoms associated with nonallergic, noninfectious triggers with no clear etiology.
[51]
Cough - StatPearls - NCBI Bookshelf - NIH
It is determined that two factors are necessary for GERD to induce a cough: spontaneous gastroesophageal reflux disease and the propensity to cough. Therefore, ...
[52]
Here's why we don't have a cold vaccine. Yet.
... viruses. And a team at Emory University has developed a vaccine that appears to protect monkeys from around a third of rhinoviruses. There's ...
[53]
Why is there no common-cold vaccine?
Oct 8, 2025 · We did look at developing an mRNA vaccine for rhinoviruses, but in the end, we decided to go with a protein vaccine with an adjuvant.
[54]
Why Is There No Vaccine for the Common Cold? - Verywell Health
Research on the development of a common cold vaccine suggests that a vaccine for the common cold is not likely in the near future. A study that compiled past ...
[55]
Influenza Antiviral Medications: Summary for Clinicians - CDC
Dec 8, 2023 · Antiviral medications with activity against influenza viruses are an important adjunct to influenza vaccine in the control of influenza.
[56]
Advances in the Treatment of Enterovirus-D68 and Rhinovirus ...
Jun 1, 2025 · Although both drugs remain experimental, results from a phase II clinical trial of vapendavir are expected in summer 2025 [83,89,90].
[57]
[PDF] HUMIDIFICATION FOR INFECTION CONTROL - Condair
Empirical studies have shown that maintaining the humidity above 40%RH with humidifiers during the winter is an effective infection control mechanism against ...
[58]
Keeping indoor humidity levels at a “sweet spot” may reduce spread ...
Nov 16, 2022 · Maintaining an indoor relative humidity between 40 and 60 percent is associated with relatively lower rates of Covid-19 infections and deaths.<|separator|>
[59]
Air Cleaners, HVAC Filters, and Coronavirus (COVID-19) | US EPA
Dec 5, 2024 · When used properly, air cleaners and HVAC filters can help reduce airborne contaminants including viruses in a building or small space.
[60]
Taking Steps for Cleaner Air for Respiratory Virus Prevention - CDC
Aug 18, 2025 · To reduce the risk of exposure, it helps to improve air quality by increasing airflow, cleaning the air with air purifiers, or opting to gather ...
[61]
Preventing Spread of Respiratory Viruses When You're Sick - CDC
Aug 18, 2025 · *Symptoms may include but are not limited to chest discomfort, chills, cough, decrease in appetite, diarrhea, fatigue (tiredness), fever or ...Masks · Taking Steps for Cleaner Air · Testing · Communication Resources<|control11|><|separator|>
[62]
Staying home to prevent the spread of respiratory viruses - Mass.gov
Although not required, choosing to stay home for about 72 hours may help reduce the chances that you spread the virus to others.<|control11|><|separator|>
[63]
Cold remedies: What works, what doesn't, what can't hurt - Mayo Clinic
Jul 12, 2024 · Drink plenty of fluids. Water, juice, clear broth or warm lemon water with honey helps loosen stuffiness, called congestion. These also help ...
[64]
[PDF] Preventing and Managing Common Cold - CDC
Some symptoms, especially runny or stuffy nose and cough, can last for up to 10 to 14 days. Those symptoms should improve over time. Colds can have similar ...
[65]
Warm-mist versus cool-mist humidifier: Which is better for a cold?
Humidifiers add moisture to the air. Cool-mist humidifiers may help ease coughing and congestion due to a cold. But more research is needed. Some research ...
[66]
[PDF] Preventing and Treating Common Cold | CDC
Some symptoms, especially runny or stuffy nose and cough, can last for up to 10 to 14 days. Those symptoms should improve over time. Colds can have similar ...
[67]
Neti pot: Can it clear my nose? - Mayo Clinic
You might use a neti pot to treat symptoms of nasal allergies, sinus problems or colds. Using a neti pot can help when indoor air dries out nasal passages.
[68]
Saline nasal irrigation for acute upper respiratory tract infections - PMC
As well as relieving sinonasal symptoms, saline irrigation may remove infectious material from the sinuses and reduce cough associated with postnasal drip ( ...
[69]
How to Safely Rinse Sinuses | Naegleria fowleri Infection - CDC
When rinsing your sinuses or nasal passages, use store-bought distilled or sterilized water, or tap or faucet water that's been boiled and cooled. Woman rinsing ...
[70]
Cold remedies: What works, what doesn't, what can't hurt
Jan 15, 2021 · Stay hydrated. Water, juice, clear broth or warm lemon water with honey helps loosen congestion and prevents dehydration. · Rest. Your body needs ...
[71]
The effectiveness of various gargle formulations and salt water ... - NIH
Oct 15, 2021 · Salt water gargling has long been recognised as a popular home remedy to alleviate symptoms for sore throat and colds. An on-going study is ...
[72]
Guaifenesin (oral route) - Side effects & dosage - Mayo Clinic
Jan 31, 2025 · Guaifenesin is used to help clear mucus or phlegm (pronounced flem) from the chest when you have congestion from a cold or flu.Missing: productive | Show results with:productive
[73]
Role of guaifenesin in the management of chronic bronchitis and ...
Dec 11, 2017 · Guaifenesin, a mucoactive drug, acts by loosening mucus in the airways and making coughs more productive. It is used for relief of wet cough ...Mucus In Airway Function And... · Pharmacology · Guaifenesin Drug Products...
[74]
Nasal decongestants in monotherapy for the common cold - Deckx, L
Oct 17, 2016 · For multiple doses of nasal decongestants, the current evidence suggests that these may have a small positive effect on subjective measures of ...Nasal Decongestants In... · Abstract · Main Results
[75]
Nasal decongestants in monotherapy for the common cold - PMC
For multiple doses of nasal decongestants, the current evidence suggests that these may have a small positive effect on subjective measures of nasal congestion ...
[76]
PRAC starts safety review of pseudoephedrine-containing medicines
Feb 10, 2023 · Pseudoephedrine-containing medicines have a known risk of cardiovascular and cerebrovascular ischaemic events (side effects involving ischaemia ...
[77]
Antihistamines for the common cold - De Sutter, AIM - 2015
Nov 29, 2015 · On the basis of this review, there is insufficient evidence to support the prescribing or purchasing over‐the‐counter antihistamines for common ...<|separator|>
[78]
Antihistamines for the common cold: Where's the evidence? - Healio
Sep 19, 2019 · Authors of a 2018 review on the effectiveness of treatments for the common cold concluded that there is no evidence to support the effectiveness ...
[79]
Acetaminophen (paracetamol) for the common cold in adults - PMC
One study showed that acetaminophen was superior to placebo in decreasing rhinorrhoea severity, but was not superior for treating sneezing and coughing.
[80]
Treatment of the Common Cold | AAFP
Sep 1, 2019 · Ibuprofen is more effective than acetaminophen for reducing fever-related discomfort.Abstract · Prevention · Treatment for Adults · Children
[81]
Efficacy and safety of over‐the‐counter analgesics in the treatment ...
Jul 10, 2006 · The review establishes that aspirin, paracetamol and ibuprofen are safe in OTC doses and that there is no evidence for any difference between the medicines.
[82]
Objective and self‐reported evidence of dextromethorphan ...
May 26, 2023 · Compared with placebo, DXM treatment reduced cough rates 21.0% over 24 h (primary endpoint) and 25.5% during daytime/awake hours. In addition, ...
[83]
Treatment of the Common Cold | AAFP
Feb 15, 2007 · Dextromethorphan may be beneficial in adults with cough, but its effectiveness has not been demonstrated in children and adolescents. Codeine ...Abstract · Traditional Pharmacologic... · Complementary and...
[84]
Dextromethorphan - StatPearls - NCBI Bookshelf - NIH
Dextromethorphan received FDA approval in 1958 for its use as a cough suppressant. It is one of the most common compounds found in most over-the-counter ...
[85]
Safety and Efficacy Evaluation of Pleconaril for Treatment of the ...
Aug 6, 2025 · In March 2002, the Antiviral Drugs Advisory Committee of the FDA voted to not recommend pleconaril for approval for the treatment of cold in ...
[86]
Antibiotic Use in Acute Upper Respiratory Tract Infections - AAFP
Nov 7, 2022 · Antibiotics should not be used for the common cold, influenza, COVID-19, or laryngitis. Evidence supports antibiotic use in most cases of acute ...
[87]
Shortcomings in the Cochrane review on zinc for the common cold ...
The review concluded that “On the basis of this review, the current evidence is insufficient to provide firm conclusions or recommend zinc supplementation.Introduction · Cochrane review on zinc for... · Discussion
[88]
Vitamin C reduces the severity of common colds: a meta-analysis
Dec 11, 2023 · In our Cochrane review on vitamin C and the common cold, we found that regular vitamin C supplementation of ≥ 0.2 g/day shortened the duration ...
[89]
Vitamin C for the common cold and pneumonia - PubMed
Jan 30, 2025 · In 15 trials (n = 6244), regular supplementation of 1 g or more of vitamin C per day decreased the severity of colds by 15%. Results of ...
[90]
Echinacea for preventing and treating the common cold - 2014
Feb 20, 2014 · We reviewed 24 controlled clinical trials with 4631 participants investigating the effectiveness of several different Echinacea preparations ...
[91]
Elderberry for prevention and treatment of viral respiratory illnesses
Apr 7, 2021 · Elderberry may be a safe option for treating viral respiratory illness, and there is no evidence that it overstimulates the immune system.
[92]
Orally Ingested Probiotics, Prebiotics, and Synbiotics as ...
Probiotics for preventing upper respiratory tract infections in adults: a systematic review and meta-analysis of randomized controlled trials. Evid-Based ...Methods · Results · Study Selection And...
[93]
Preventive and curative effects of acupuncture on the common cold
The use of acupuncture for symptoms of the common cold symptoms should be considered, although further evidence from placebo controlled RCTs is required.
[94]
Homeopathic medicinal products for preventing and treating acute ...
Dec 13, 2022 · Many treatments are used to control symptoms and shorten illness duration. Most treatments have minimal benefit and may lead to adverse events.
[95]
The treatment of rhinovirus infections: progress and potential - PMC
The usual cold lasts about a week, although 25% last 2 weeks (Gwaltney et al., 1967). Virus shedding persists after the resolution of symptoms and virus may be ...
[96]
Prevention and treatment of the common cold: making sense ... - NIH
The common cold is an acute, self-limiting viral infection of the upper respiratory tract involving the nose, sinuses, pharynx and larynx.
[97]
Can I Catch the Same Cold Twice? - The New York Times
Mar 9, 2018 · Yes, you can catch the same cold twice, depending on the strength of your immune response. Most of what we know about immunity to cold viruses is based on ...
[98]
The common cold in adults: Diagnosis and clinical features
Oct 31, 2023 · The average incidence of the common cold is five to seven episodes per year in preschool children, and two to three per year by adulthood [3].
[99]
The Common Cold - PMC - PubMed Central - NIH
The differential diagnosis of a cold includes allergic rhinitis, vasomotor rhinitis, intranasal foreign body, and sinusitis. A diagnosis of allergic rhinitis ...
[100]
Respiratory Viral Infections in Immunocompetent ... - PubMed Central
A variety of complications of viral respiratory infection have been ... secondary bacterial infections causing otitis media, sinusitis, or pneumonia.
[101]
Rhinovirus-Induced Exacerbations of Asthma and COPD - PMC - NIH
Respiratory viral infections cause exacerbations of asthma and COPD. This is evidenced by the increased identification of viruses in the respiratory tract ...
[102]
Respiratory Viral and Bacterial Exacerbations of COPD—The Role ...
At the onset of exacerbations 35% of patients report cold-like symptoms [11], and it is clear that exacerbations of COPD are frequently associated with viral ...
[103]
Cardiovascular Complications of Viral Respiratory Infections ... - NIH
Dec 27, 2022 · Influenza myocarditis is considered infrequent but associated with a poor outcome, with a mortality rate ranging up to 30% in H1N1 subtype ...Missing: immunocompromised | Show results with:immunocompromised
[104]
Olfactory dysfunction during COVID-19 pandemic - PMC
Post-infectious hyposmia/anosmia (common cold, flu) may impair the sense of smell due to a combined inflammatory/conductive and neurodegenerative disorder.
[105]
Smoking increases the risk of infectious diseases: A narrative review
Smoking is one of the main risk factors for infections in the respiratory tract, digestive tract, reproductive tract, and other systems in humans.
[106]
The Common Cold - PMC - PubMed Central - NIH
Transmission. In general, respiratory viruses are spread by three mechanisms: small-particle aerosols, large-particle aerosols, and direct contact.
[107]
Do people living in the tropics get fewer cold and flu viruses?
Oct 29, 2018 · But do people living in hot, humid regions suffer lower incidence of cold and flu? That was the question posed by reader Wesley Folitarik. "We ...
[108]
https://pmc.ncbi.nlm.nih.gov/articles/PMC7124320/
[109]
Factors associated with outcome in a national cohort of rhinovirus ...
Nov 9, 2024 · Around 70% of the global burden and mortality from acute lower respiratory tract infections is caused by children in developing countries.The ...<|control11|><|separator|>
[110]
Roles of Humidity and Temperature in Shaping Influenza Seasonality
Thus, exposure to cold air outside or dry air inside during the wintertime may increase influenza virus transmission and potentially trigger a flu season. FIG 1 ...
[111]
Seasonality of influenza and other respiratory viruses - EMBO Press
Feb 14, 2022 · The lower temperatures during the winter season in temperate climates may confine people to indoor activities with indoor crowding, which could ...Missing: incidence | Show results with:incidence
[112]
Cold temperature and low humidity are associated with increased ...
Cold temperature and low humidity were associated with increased occurrence of RTIs, and a decrease in temperature and humidity preceded the onset of the ...
[113]
Association between viral seasonality and meteorological factors
Jan 30, 2019 · Rhinovirus also has two peaks, a major peak around October-November and a minor peak in March. Adenovirus has a smaller peak in March-April.
[114]
Flu cases plummet after winter, spring breaks in schools, study ...
Jan 17, 2024 · Cases of influenza-like illness (ILI) among students in a Wisconsin school district dropped by nearly half after winter and spring breaks.<|separator|>
[115]
Rhinoviruses - PMC - PubMed Central - NIH
HRVs circulate throughout the year but usually with a bimodal peak in temperate locations in both hemispheres. The highest peaks, mostly defined using adult ...
[116]
Common Cold | Johns Hopkins Medicine
Research has shown that rhinoviruses may survive up to 3 hours outside of the nasal lining. When should I call my healthcare provider? If your symptoms get ...
[117]
THE COMMON COLD - PMC - PubMed Central
It has been defined as an acute epidemic respiratory disease characterized by mild coryzal symptoms of rhinorrhea, nasal obstruction, and sneezing.Missing: overview | Show results with:overview
[118]
A Common-Sense Guide to the Common Cold for Older Adults
Sep 11, 2024 · Even a minor cold can be dangerous for older adults, whose immune systems don't fight off pathogens as effectively as they once did. While the ...
[119]
Common Cold - WebMD
Mar 15, 2024 · In families with children in school, the number of colds per child can be as high as 12 a year. Adults average about 2 to 4 colds a year, ...
[120]
Sex Differences in Influenza: The Challenge Study Experience
Aug 23, 2021 · Males were 16% less likely to have symptoms of influenza than females, though the likelihood of viral shedding was similar. Males had a median 4 ...Abstract · MATERIALS AND METHODS · RESULTS · Discussion
[121]
Seasonality of influenza and other respiratory viruses - PMC - NIH
Feb 14, 2022 · Overall, seasonality is more pronounced with greater distance from the equator, and tends to be less pronounced in regions closer to the equator ...
[122]
Climate warming and influenza dynamics: the modulating effects of ...
Feb 25, 2025 · Results show warming significantly influences infections across seasonal, interannual, and decadal scales. Higher temperatures significantly impact infection ...
[123]
Climate Change's Impact on Flu Seasons: New Study Insights
May 2, 2025 · If global warming continues, warm winters will become more common, and the impact of flu will likely be more heavily felt, say the study's ...
[124]
Common cold: The centuries-old battle against the sniffles - BBC News
Oct 4, 2011 · The ancient Greek physician Hippocrates, who pioneered the practice of clinical observation, believed colds were caused by a build-up of waste ...
[125]
The Cold or Catarrh in the Late 1800s - geriwalton.com
Mar 22, 2019 · Many doctors of the late 1800s wrote about and investigated the cold, or at it was often called, catarrh.
[126]
None
Nothing is retrieved...<|control11|><|separator|>
[127]
Human Rhinoviruses - PMC - PubMed Central - NIH
Human rhinoviruses (HRVs), first discovered in the 1950s, are responsible for more than one-half of cold-like illnesses and cost billions of dollars annually.
[128]
Origin of Patent Medicines - National Museum of American History
The term “patent medicine” came to describe all pre-packaged medicines sold “over-the-counter” without a doctor's prescription.
[129]
There's a Cure for That: Historic Medicines and Cure-alls in America
Digital exhibit on early patent medicines, cure-alls, and pharmaceuticals to trace the development of trade medicines in the United States.
[130]
Bayer patents aspirin | March 6, 1899 - History.com
Nov 24, 2009 · The German company Bayer patents aspirin on March 6, 1899. Now the most common drug in household medicine cabinets, acetylsalicylic acid was originally made ...
[131]
The Story of Aspirin - National Library of Medicine
In 1860, Hermann Kolbe (1818–1884), a German scientist, created a method to synthesize salicylic acid, the building block of aspirin, from smaller molecules, ...
[132]
The common cold - The Lancet
Jan 4, 2003 · More than 100 different serotypes of rhinoviruses have been identified, the relative prevalences of which seem to vary between different ...
[133]
Treatment of the Common Cold in Children and Adults - AAFP
Jul 15, 2012 · Generally caused by viruses, the common cold is treated symptomatically. Antibiotics are not effective in children or adults.Missing: mid | Show results with:mid
[134]
The Cold-Cure Merry-Go-Round - The Atlantic
In 1949, five more reports recommending antihistamine treatment for colds were published in medical journals. The claims varied from those of simple relief of ...
[135]
Rulemaking History for OTC Nasal Decongestant Drug Products - FDA
Feb 28, 2022 · The Status of Over-the-Counter (OTC) Rulemakings contains the citation number of the Federal Register notices organized by therapeutic ...
[136]
Over-the-counter Cold Medications: A Critical Review of Clinical ...
May 5, 1993 · Objective.—To determine whether over-the-counter cold medications have been shown to be effective in relieving symptoms in children, ...
[137]
Zinc gluconate and the common cold: a controlled clinical study
A report in 1984 on the success of zinc gluconate against common cold symptoms could not be confirmed in three subsequent studies.Missing: 1980s | Show results with:1980s
[138]
Efficacy of Zinc Against Common Cold Viruses: An Overview - PMC
The results of the first clinical trial of intranasal zinc for the common cold were reported in 2000. Clinical Trials of Zinc. The effects of lozenge or ...
[139]
Impact of the COVID-19 pandemic on antiviral drug development for ...
The coronavirus disease 2019 (COVID-19) pandemic indirectly resulted in missed therapeutic opportunities for many diseases. Here we focus on community-acquired ...
[140]
Popular Cold Medicines Are Pulled From Market
Nov 7, 2000 · Safety concerns about phenylpropanolamine first emerged in the early 1980's, when the food and drug agency began receiving reports that some ...
[141]
FDA Proposes Ending Use of Oral Phenylephrine as OTC ...
Nov 7, 2024 · FDA is proposing to end the use of oral phenylephrine as an active ingredient from OTC Monograph M012 for the temporary relief of nasal ...Missing: debate | Show results with:debate
[142]
Hidden in plain sight: the impact of human rhinovirus infection in adults
Mar 28, 2025 · Since its initial identification by Winston Price in the 1950s, human rhinovirus (HRV) has become recognised as one of the most common agents ...
[143]
Altesa BioSciences Presents Findings Demonstrating Beneficial ...
Sep 28, 2025 · Treatment improved patient reported outcomes, reduced viral load, and maintained lung function compared to placebo; Multi-center, ...
[144]
Altesa BioSciences Details Positive Topline Vapendavir Results ...
May 7, 2025 · Antiviral improved overall patient-reported measures of both upper, lower respiratory symptoms, shortened overall course of illness.
[145]
Vapendavir for rhinovirus-triggered COPD exacerbations: phase 2a ...
Oct 2, 2025 · A phase 2a study presented at ERS 2025 explored the potential of vapendavir, an oral antiviral, to treat rhinovirus-triggered COPD exacerbations ...
[146]
Opportunities for rhinovirus-targeted RNA therapeutics: A narrative ...
This narrative review provides an update on RV virology and epidemiology, an overview of attempts to develop treatments for RV, and describes recent advances ...
[147]
Using the Ferret as an Animal Model for Investigating Influenza ...
To date, the ferret remains as one of the preferred models for assessing influenza infection and as such has become an important model for antiviral testing.
[148]
Developing a vaccine for human rhinoviruses - PMC - NIH
Attempts to produce a protective vaccine to RV's have failed due to the large number of antigenically distinct serotypes and the lack of a suitable small animal ...
[149]
Development of Rhinovirus Vaccines - Creative Diagnostics
Early Attempts at HRV Vaccines. During the late 1960s and early 1970s clinical trials were performed to investigate a common cold vaccine, largely through ...
[150]
Clinical Significance of Rhinoviruses and Progress Toward ... - NIH
Jul 9, 2025 · Despite their substantial disease burden, vaccine development for RVs has been hindered for decades due to extensive serotypic diversity and ...
[151]
Rhinovirus Biology, Antigenic Diversity, and Advancements in the ...
HRVs were first isolated in the 1950s and remain the leading cause of upper respiratory tract infections worldwide (Price, 1956; Jacobs et al., 2013).
[152]
https://pmc.ncbi.nlm.nih.gov/articles/PMC12193398/
[153]
Should Participation in Vaccine Clinical Trials be Mandated?
Society is unlikely to accept compulsory recruitment to a trial for a vaccine against the common cold if the vaccine causes severe complications in vaccinees.
[154]
Ethical Issues and Vaccines - HistoryOfVaccines.org
The key ethical debates related to vaccine regulation, development, and use generally revolve around (1) mandates, (2) research and testing, (3) informed ...
[155]
2025-2026 Respiratory Disease Season Outlook | CFA - CDC
Aug 25, 2025 · This is a high-level assessment intended to provide information on how the 2025-2026 respiratory season could unfold, and it is not a precise ...
[156]
Immunizations for Respiratory Viruses Prevention - CDC
Aug 18, 2025 · Immunizations help prepare your body to defend itself from viruses and severe illness. Some immunizations teach your immune system what the virus looks like.
[157]
The Economic Burden of Non–Influenza-Related Viral Respiratory ...
Feb 24, 2003 · Direct medical costs represent about 45% ($17 billion) of the total, and indirect costs represent about 55% ($22.5 billion) of the total costs.
[158]
https://www.creative-diagnostics.com/development-of-rhinovirus-vaccines.htm
[159]
The common cold coughs up $40 billion annual price tag | EurekAlert!
Feb 24, 2003 · The study reports that an estimated 189 million school days (an average of nearly 1 day per episode) are missed annually due to a cold. As a ...<|separator|>
[160]
Productivity losses related to the common cold - PubMed
Each cold experienced by a working adult caused an average of 8.7 lost work hours (2.8 absenteeism hours; 5.9 hours of on-the-job loss), and 1.2 work hours ...
[161]
[PDF] SURVEY DATA ON THE BUSINESS BURDEN
Dec 4, 2024 · Furthermore, the cost of worker ill-health to businesses has increased by. £30 billion since 2018, with £25 billion of this being attributable ...
[162]
The rise in remote work since the pandemic and its impact on ...
Oct 31, 2024 · We examine the pandemic-period relationships between the rise in the percentage of workers primarily working from home and the percent change in total factor ...Missing: 2025 | Show results with:2025
[163]
https://www.atsjournals.org/doi/abs/10.1164/ajrccm.2025.211.Abstracts.A3550
[164]
Costs of common cold nothing to sneeze at | CBC News
Feb 24, 2003 · Costs of drugs, doctors visits, missed work from common cold add up to $39.5 billion a year in the U.S., researchers say.
[165]
The social and economic benefits of improved hand hygiene
Jan 18, 2023 · Even seasonal transmissible illnesses, such as the common cold, are estimated to cost between $25 and $40bn annually. ... benefits as a result of ...
[166]
Hand hygiene to reduce community transmission of influenza and ...
Oct 8, 2012 · Hand hygiene is a simple, low‐cost, non‐pharmaceutical intervention that was recommended by local, national and international health agencies ...